Christopher H Van Dyck, MD

Professor of Psychiatry, Neurology, and Neuroscience; Director, Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric Psychiatry

Clinical Interests

  • Alzheimer Disease

Patient Care

Accepts new patients? Yes
Patient Type: Geriatric
Referrals: From patients or physicians

Patient Care Organizations

Psychiatry: Alzheimer's Disease Research Unit

Dorothy Adler Geriatric Assessment Center

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Psychiatry AB of Psychiatry & Neurology (1991)

  • Geriatric Psychiatry AB of Psychiatry & Neurology (1994)

Clinical Trials

Conditions Study Title
Aging, Mental Health & Behavioral Research CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
Aging, Mental Health & Behavioral Research Apathy in Dementia Methylphenidate Trial 2 (ADMET2)
Aging, Mental Health & Behavioral Research 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)
Aging, Diseases of the Nervous System, Mental Health & Behavioral Research A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Aging, Mental Health & Behavioral Research Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)
Aging, Mental Health & Behavioral Research Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)
Aging, Diseases of the Nervous System, Mental Health & Behavioral Research A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Aging, Mental Health & Behavioral Research Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

Edit this profile

Contact Info

Christopher H Van Dyck, MD
Patient Care Locations
Yale Alzheimer's Disease Research Unit1 Church Street, Ste Suite 600
New Haven, CT 06510
View on map...
Adler Geriatric Assessment Center874 Howard Avenue
New Haven, CT 06519
View on map...
Mailing Address
Yale University School of Medicine
One Church Street

New Haven, CT 06510

Alzheimer's Disease Research Unit

Research Image 1

Frequency of psychosis by ApoE e4 carrier status and dementia severity. Mini Mental State Examination (MMSE) score was used to classify AD patients as mild (MMSE>19, n=103), moderate (MMSE=12-19, n=121), or severe (MMSE<12, n=42). Separate multiple logistic regression analyses were performed for each severity category, with presence of psychosis as dependent variable and the following independent variables (in addition to e4 carrier status): age, sex, educational attainment, and MMSE. *Only at the severe stage was the presence of e4 significantly associated with psychosis (odds ratio [OR]=16.61, 95% CI=2.11-130.51, P=.008). (From Zdanys KF , et al. 2007.)